{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-045663","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.379188+00:00","generated_at":"2026-06-19T03:02:50.840585+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio Q4 net loss $0.92/sh; cash $466M; board adds McCormick; acoramidis data mid-2023","bullets":["Net loss attributable to common stockholders $137.6M in Q4 ($0.92/sh); full year $481.2M ($3.26/sh).","Cash, equivalents, marketable securities $466.2M at Dec 31, 2022, down from $787.7M; provides runway into 2024.","Phase 3 ATTRibute-CM trial of acoramidis for ATTR-CM topline data expected mid-2023.","Phase 2 PROPEL 2 infigratinib cohort 5 data expected March 2023; Phase 3 initiation planned 2023.","Board changes: Richard Scheller and Brenton Saunders resigned; Frank McCormick appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-045663","json":"https://secwatch.observer/filing/0001193125-23-045663.json","markdown":"https://secwatch.observer/filing/0001193125-23-045663.md","text":"https://secwatch.observer/filing/0001193125-23-045663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/d472572d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:02:50.840585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e63b6c9472bb792ac05fe1354b18de627e8a112","claim":"BridgeBio Pharma, Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e1c0357c805033615af57fc8caa77e523936d5a9","claim":"BridgeBio Pharma, Inc. reported financial results for the full year ended December 31, 2022.","evidence_excerpt":"BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"16802e9a4e","claim":"Richard H. Scheller resigned as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2cfae31502","claim":"Brenton L. Saunders resigned as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"90e0f270d1","claim":"Frank McCormick was appointed as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"On February 23, 2023, the Company announced that Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has been appointed by the Board to serve as a director of the Company and fill the vacancy created by the resignation of Dr. Scheller.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}